Literature DB >> 2209329

Comparison of HbA1 and fructosamine in diagnosis of glucose-tolerance abnormalities.

P J Guillausseau1, M A Charles, F Paolaggi, J Timsit, P Chanson, J Peynet, V Godard, E Eschwege, F Rousselet, J Lubetzki.   

Abstract

Total glycosylated hemoglobin (HbA1) and fructosamine were evaluated as screening tools for detection of glucose-tolerance abnormalities in 144 asymptomatic subjects undergoing a 75-g oral glucose tolerance test. Subjects were classified according to World Health Organization criteria as having normal (n = 78), impaired (n = 40), or diabetic (n = 26) glucose tolerance. We found good specificity for HbA1 and fructosamine (100 and 97%, respectively) but low sensitivity (15 and 19%, respectively). At the intersection of the curves of sensitivity and specificity drawn from various thresholds of normality, both sensitivity and specificity were 75% for HbA1 and 55% for fructosamine. Thus, neither HbA1 nor fructosamine seems to be suitable for the diagnosis of mild abnormalities in glucose tolerance.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2209329     DOI: 10.2337/diacare.13.8.898

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  4 in total

1.  Use of HbA(1c) in screening for Cuban-Americans with undiagnosed type 2 diabetes.

Authors:  Fatma G Huffman; Joel C Exebio; Gustavo G Zarini; Cristobal Exebio
Journal:  J Immigr Minor Health       Date:  2011-06

2.  Type 2 diabetes mellitus in Navajo adolescents.

Authors:  C Kim; C McHugh; Y Kwok; A Smith
Journal:  West J Med       Date:  1999-04

3.  A review of glycated albumin as an intermediate glycation index for controlling diabetes.

Authors:  H Vernon Roohk; Asad R Zaidi
Journal:  J Diabetes Sci Technol       Date:  2008-11

4.  Diagnostic criteria for diabetes revisited: making use of combined criteria.

Authors:  Ali Parappil; Suhail AR Doi; Kamal AS Al-Shoumer
Journal:  BMC Endocr Disord       Date:  2002       Impact factor: 2.763

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.